NZ592444A - Vaccine compositions comprising a mutated factor h binding protein - Google Patents

Vaccine compositions comprising a mutated factor h binding protein

Info

Publication number
NZ592444A
NZ592444A NZ592444A NZ59244409A NZ592444A NZ 592444 A NZ592444 A NZ 592444A NZ 592444 A NZ592444 A NZ 592444A NZ 59244409 A NZ59244409 A NZ 59244409A NZ 592444 A NZ592444 A NZ 592444A
Authority
NZ
New Zealand
Prior art keywords
binding protein
factor
vaccine compositions
mutated factor
seq
Prior art date
Application number
NZ592444A
Other languages
English (en)
Inventor
Rachel Exley
Christoph Tang
Susan M Lea
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Priority to NZ601538A priority Critical patent/NZ601538A/en
Publication of NZ592444A publication Critical patent/NZ592444A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ592444A 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein NZ592444A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ601538A NZ601538A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0819633.9A GB0819633D0 (en) 2008-10-25 2008-10-25 Composition
PCT/GB2009/051439 WO2010046715A1 (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Publications (1)

Publication Number Publication Date
NZ592444A true NZ592444A (en) 2012-11-30

Family

ID=40133849

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ592444A NZ592444A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein
NZ601538A NZ601538A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ601538A NZ601538A (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Country Status (23)

Country Link
US (1) US20120052092A1 (enExample)
EP (2) EP3501534B1 (enExample)
JP (2) JP5676458B2 (enExample)
KR (3) KR20170000390A (enExample)
CN (2) CN102245202A (enExample)
AU (1) AU2009306114B2 (enExample)
BR (1) BRPI0919926A2 (enExample)
CA (1) CA2741619A1 (enExample)
CO (1) CO6382140A2 (enExample)
DK (1) DK3501534T5 (enExample)
ES (1) ES2970878T3 (enExample)
FI (1) FI3501534T3 (enExample)
GB (1) GB0819633D0 (enExample)
HR (1) HRP20240226T1 (enExample)
HU (1) HUE065348T2 (enExample)
LT (1) LT3501534T (enExample)
MX (1) MX2011004322A (enExample)
NZ (2) NZ592444A (enExample)
PL (1) PL3501534T3 (enExample)
PT (1) PT3501534T (enExample)
RU (1) RU2559528C2 (enExample)
SI (1) SI3501534T1 (enExample)
WO (1) WO2010046715A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
US9266942B2 (en) 2009-04-30 2016-02-23 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHbp) and methods of use
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
US20160030544A1 (en) * 2013-03-14 2016-02-04 Isis Innovation Limited Immunogenic composition to neisseria
WO2015017817A1 (en) 2013-08-02 2015-02-05 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
AU2015304079B2 (en) * 2014-08-20 2021-05-13 Stichting Sanquin Bloedvoorziening Factor H potentiating antibodies and uses thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
EP3897706A4 (en) 2018-12-21 2022-11-23 Griffith University COMPOSITIONS, METHODS AND USES FOR INDURING AN IMMUNE RESPONSE
AU2020309556A1 (en) * 2019-07-08 2022-03-03 Crapaud Bio, Inc. Methods of making and using lipooligosaccharide compositions and vaccines
JP7631296B2 (ja) 2019-07-17 2025-02-18 ジェミニ・セラピューティクス・サブ・インコーポレイテッド Ｈ因子増強性抗体及びその使用
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
BRPI0409459A (pt) * 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
CN101107007B (zh) * 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2007263531B2 (en) * 2006-06-29 2012-03-15 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
WO2011024072A2 (en) * 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
TR201802933T4 (tr) * 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.

Also Published As

Publication number Publication date
SI3501534T1 (sl) 2024-03-29
AU2009306114B2 (en) 2015-10-01
BRPI0919926A2 (pt) 2016-02-16
KR20110092282A (ko) 2011-08-17
AU2009306114A1 (en) 2010-04-29
RU2559528C2 (ru) 2015-08-10
EP3501534A1 (en) 2019-06-26
DK3501534T3 (da) 2024-02-05
ES2970878T3 (es) 2024-05-31
CA2741619A1 (en) 2010-04-29
KR20170000390A (ko) 2017-01-02
HUE065348T2 (hu) 2024-05-28
CN102245202A (zh) 2011-11-16
PL3501534T3 (pl) 2024-04-02
PT3501534T (pt) 2024-02-07
JP6076326B2 (ja) 2017-02-08
EP3501534B1 (en) 2023-11-29
LT3501534T (lt) 2024-03-12
JP5676458B2 (ja) 2015-02-25
MX2011004322A (es) 2011-06-16
JP2012506411A (ja) 2012-03-15
EP2355845B1 (en) 2018-12-05
CO6382140A2 (es) 2012-02-15
NZ601538A (en) 2014-01-31
US20120052092A1 (en) 2012-03-01
KR20190011836A (ko) 2019-02-07
GB0819633D0 (en) 2008-12-03
WO2010046715A1 (en) 2010-04-29
EP2355845A1 (en) 2011-08-17
HRP20240226T1 (hr) 2024-05-10
JP2015063558A (ja) 2015-04-09
CN105412920A (zh) 2016-03-23
FI3501534T3 (fi) 2024-02-09
RU2011120706A (ru) 2012-11-27
DK3501534T5 (da) 2024-09-02

Similar Documents

Publication Publication Date Title
PH12018501517A1 (en) Neisseria meningitidis compositions and methods thereof
NZ601538A (en) Vaccine compositions comprising a mutated factor h binding protein
NZ622048A (en) Hybrid polypeptides including meningococcal fhbp sequences
WO2010127172A3 (en) Chimeric factor h binding proteins (fhbp) and methods of use
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
NZ707439A (en) Modified factor ix polypeptides and uses thereof
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP2567707A3 (en) Composition of tumour-associated peptides and related anti-cancer vaccine
PE20120425A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
EP3444352A3 (en) Production of recombinant vaccine in e. coli by enzymatic conjugation
WO2009023300A3 (en) Mutants of cholesterol-dependent cytolysins and uses thereof
NZ603200A (en) Peptides and their use
NZ607069A (en) Modified relaxin polypeptides and their uses
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
NZ701125A (en) Improved chymosine enzyme variants
NZ597923A (en) Protein glycosylation
NZ586430A (en) Mutant forms of streptolysin o (slo)
NZ594268A (en) Grass peptides for vaccine
NZ601488A (en) Immunogenic proteins and compositions
WO2009072555A1 (ja) 癌ワクチン
PH12013502292A1 (en) Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
AU2011350442B2 (en) Modified tamavidin
NZ593200A (en) Peptide adjuvants
GB201211586D0 (en) Japanese cedar peptides for preventing or treating allergy
吴雪莲 Let’s live in a world full of understanding!

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 OCT 2016 BY FB RICE

Effective date: 20131018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2017 BY RENEWALS TEAM

Effective date: 20161018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2018 BY RENEWALS TEAM

Effective date: 20171012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2019 BY SERVICE TEAM

Effective date: 20180730

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2020 BY RENEWALS TEAM

Effective date: 20191017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2021 BY RENEWALS TEAM

Effective date: 20201019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2022 BY RENEWALS TEAM

Effective date: 20211023

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2023 BY ENVOY

Effective date: 20221014

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2024 BY ANAQUA SERVICES

Effective date: 20230921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2025 BY ANAQUA SERVICES

Effective date: 20240920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 OCT 2026 BY ANAQUA SERVICES

Effective date: 20250924